GlassScriptPhysician profile
Clifton J Bailey
NPI 1679598833
$5,743.32
in general payments reported to CMS, 2019-2025
39 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2021: $504 · 2022: $1,265 · 2023: $915 · 2024: $791 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $987.36 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Jazz Pharmaceuticals INC. | $550.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $462.37 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Insmed, INC. | $403.67 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $337.28 | 2022-2025 | |
| Mylan Specialty L.P. | $308.35 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $287.29 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $275.83 | 2019-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $242.67 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $226.60 | 2021-2025 | Dupixent |
| Harmony Biosciences LLC | $178.80 | 2022-2025 | Wakix |
| Pulmonx Corporation | $129.11 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $125.05 | 2023-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $122.83 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $116.31 | 2024-2025 | Purified Cortrophin Gel |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $111.48 | 2021-2023 | Belsomra, Keytruda |
| Viatris Specialty LLC | $98.42 | 2025 | Yupelri |
| Verona Pharma, INC. | $95.29 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $77.29 | 2019-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $75.32 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $63.73 | 2025 | Lumryz |
| Baxter Healthcare | $49.23 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Vifor Pharma, INC. | $46.95 | 2025 | Zemaira |
| Stryker Corporation | $46.63 | 2025 | Flowtriever |
| Electromed, INC. | $44.32 | 2025 | Smartvest |
| Amgen INC. | $40.29 | 2025 | Tezspire |
| Inogen, INC. | $33.37 | 2022-2025 | |
| Philips North America LLC | $23.76 | 2023 | |
| Inspire Medical Systems, INC. | $23.71 | 2024 | Inspire |
| Liquidia Technologies, INC. | $22.51 | 2025 | Yutrepia |
| Resmed Corp | $18.68 | 2022 | |
| Shionogi INC | $18.25 | 2023 | Fetroja |
| Circassia INC. | $16.98 | 2019 | |
| Fisher & Paykel Healthcare INC | $16.10 | 2021 | |
| Axsome Therapeutics, INC. | $15.68 | 2025 | Sunosi |
| Sunovion Pharmaceuticals INC. | $13.09 | 2019 | |
| Tactile Systems Technology INC | $12.92 | 2023 | Entre Plus, Flexitouch Plus |
| Novartis Pharmaceuticals Corporation | $12.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.